Discover 3 Global Penny Stocks With Market Caps Over US$30M

Amidst a backdrop of geopolitical tensions and fluctuating oil prices, global markets have experienced volatility, with major indices such as the Russell 2000 and S&P MidCap 400 facing notable declines. In times like these, investors often seek opportunities in less conventional areas of the market. Penny stocks, while an old term, continue to represent potential growth avenues for those willing to explore smaller or newer companies. Despite their reputation for riskiness, when these stocks are backed by robust financials and sound fundamentals, they can offer intriguing possibilities for value-seeking investors.

Let's explore several standout options from the results in the screener.

National Corporation for Tourism and Hotels (ADX:NCTH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: National Corporation for Tourism and Hotels (ADX:NCTH) owns, manages, and invests in hotels and leisure complexes both in the United Arab Emirates and internationally, with a market cap of AED3.18 billion.

Operations: The company's revenue is primarily derived from its hotel operations at AED995.62 million, supplemented by other services generating AED647.37 million, catering services contributing AED509.43 million, retail services at AED64.24 million, and investment properties adding AED48.87 million.

Market Cap: AED3.18B

National Corporation for Tourism and Hotels, with a market cap of AED3.18 billion, shows a mixed financial picture. While its debt is well covered by operating cash flow and interest payments are well managed, the company's return on equity is low at 5.9%. Recent earnings reports indicate stable revenue growth but declining net income and profit margins compared to the previous year. The company maintains more cash than total debt, suggesting prudent financial management despite lower profitability. Additionally, short-term assets exceed both short-term and long-term liabilities, indicating solid liquidity positions amidst ongoing operational challenges.

• Dive into the specifics of National Corporation for Tourism and Hotels here with our thorough balance sheet health report.
• Assess National Corporation for Tourism and Hotels' previous results with our detailed historical performance reports.

Uni-Bio Science Group (SEHK:690)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Uni-Bio Science Group Limited is an investment holding company that focuses on the research, development, manufacture, and sale of biological and chemical pharmaceutical products for treating human diseases in Hong Kong and the People's Republic of China, with a market cap of HK$447.84 million.

Operations: The company generates revenue from two main segments: Chemical Pharmaceutical Products, contributing HK$153.79 million, and Biological Pharmaceutical Products, accounting for HK$395.98 million.

Market Cap: HK$447.84M

Uni-Bio Science Group, with a market cap of HK$447.84 million, presents a complex investment case. Despite achieving profitability over the past five years and maintaining stable cash flow to cover debt, recent financial results show declining net income from HK$75.96 million to HK$31.17 million due to increased R&D expenses and regulatory changes impacting its biological drug business. The company's short-term assets comfortably exceed liabilities, ensuring liquidity; however, profit margins have decreased from 15.5% to 8.8%. Strategic investments in regenerative medicine and international expansion could enhance competitiveness but weigh on short-term profitability.

• Navigate through the intricacies of Uni-Bio Science Group with our comprehensive balance sheet health report here.
• Examine Uni-Bio Science Group's past performance report to understand how it has performed in prior years.

Epitomee Medical (TASE:EPIT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Epitomee Medical Ltd, with a market cap of ₪109.89 million, develops and commercializes ingestible therapeutic devices in Israel.

Operations: Epitomee Medical Ltd currently does not report any revenue segments.

Market Cap: ₪109.89M

Epitomee Medical Ltd, with a market cap of ₪109.89 million, is pre-revenue, reporting sales of US$0.565 million for the first half of 2026 and a net loss of US$4.84 million. The company has no debt and its short-term assets exceed both short-term and long-term liabilities, indicating sound liquidity management. However, it faces less than a year of cash runway based on current free cash flow trends. Despite high volatility in share price recently and negative return on equity due to unprofitability, Epitomee benefits from an experienced management team with an average tenure of 6.7 years.

• Click here to discover the nuances of Epitomee Medical with our detailed analytical financial health report.
• Gain insights into Epitomee Medical's historical outcomes by reviewing our past performance report.

Summing It All Up

• Discover the full array of 3,599 Global Penny Stocks right here.
• Want To Explore Some Alternatives? We've found 7 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com